Physical Characterization and Formulation Development of a Recombinant Pneumolysoid Protein-Based Pneumococcal Vaccine

Gray, 1980, Epidemiologic studies of Streptococcus pneumoniae in infants: Acquisition, carriage, and infection during the first 24 months of life, J Infect Dis, 142, 923, 10.1093/infdis/142.6.923 Johnston, 1991, Pathogenesis of pneumococcal pneumonia, Rev Infect Dis, 13, S509, 10.1093/clinids/13.Supplement_6.S509 O'Brien, 2009, Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates, Lancet, 374, 893, 10.1016/S0140-6736(09)61204-6 Black, 2008, 531 Jackson, 2008, 569 Iyer, 2012, Preformulationi characterization of an aluminum salt-adjuvanted trivalent recombinant protein-based vaccine candidate against Streptococcus pneumoniae, J Pharm Sci, 101, 3078, 10.1002/jps.23175 Rubins, 1998, Pneumolysin: A multifunctional pneumococcal virulence factor, J Lab Clin Med, 131, 21, 10.1016/S0022-2143(98)90073-7 Jedrzejas, 2001, Pneumococcal virulence factors: Structure and function, Microbiol Mol Biol Rev, 65, 187, 10.1128/MMBR.65.2.187-207.2001 Mitchell, 2010, Streptococcus pneumoniae: Virulence factors and variation, Clin Microbiol Infect, 16, 411, 10.1111/j.1469-0691.2010.03183.x Molloy, 2010, Bacterial pathogenicity: Pneumolysin: Stimulating protection, Nat Rev Microbiol, 9, 10.1038/nrmicro2497 Paton, 1983, Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae, Infect Immun, 40, 548, 10.1128/IAI.40.2.548-552.1983 Lock, 1992, Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae, Microb Pathog, 12, 137, 10.1016/0882-4010(92)90116-6 Alexander, 1994, Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae, Infect Immun, 62, 5683, 10.1128/IAI.62.12.5683-5688.1994 Paton, 1983, Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin, Infect Immunity, 41, 1212, 10.1128/IAI.41.3.1212-1216.1983 Ferrante, 1984, Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin, Infect Immun, 46, 585, 10.1128/IAI.46.2.585-589.1984 Kerr, 2006, Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines, Infect Immun, 74, 586, 10.1128/IAI.74.1.586-593.2006 Oloo, 2011, Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease, J Biol Chem, 286, 2133, 10.1074/jbc.M110.191148 Soltani, 2007, Specific protein-membrane contacts are required for prepore and pore assembly by a cholesterol-dependent cytolysin, J Biol Chem, 282, 15709, 10.1074/jbc.M701173200 Farrand, 2010, Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface, Proc Natl Acad Sci USA, 107, 4341, 10.1073/pnas.0911581107 Mitchell, 2011, Protective immune responses to Streptococcus pneumoniae pneumolysoids, New Orleans, Louisiana: American Society of Microbiology Mann, 2012 Wilson-Welder, 2009, Vaccine adjuvants: Current challenges and future approaches, J Pharm Sci, 98, 1278, 10.1002/jps.21523 Iyer, 2012, Formulation development of a plant-derived h1n1 influenza vaccine containing purified recombinant hemagglutinin antigen, Hum Vaccin Immunotherapeut, 8, 453, 10.4161/hv.19106 Kueltzo, 2003, Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study, J Pharm Sci, 92, 1805, 10.1002/jps.10439 Maddux, 2011, Multidimensional methods for the formulation of biopharmaceuticals and vaccines, J Pharm Sci, 100, 4171, 10.1002/jps.22618 Hu, 2011, Investigation of protein conformational stability employing a multimodal spectrometer, Anal Chem, 83, 9399, 10.1021/ac201995c Maddux, 2012, An improved methodoloy for multidimensional hig-throughput preformulation characterization of protein conformational stabiliity, J Pharm Sci, 101, 2017, 10.1002/jps.23132 Kim, 2012, Improved data visualization techniques for analyzing macromolecule structrual changes, Protein Sci, 21, 1540, 10.1002/pro.2144 Böhm, 1992, Quantitative analysis of protein far UV circular dichroism spectra by neural networks, Protein Eng, 5, 191, 10.1093/protein/5.3.191 Kuo, 1995, Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines, Infect Immun, 63, 2706, 10.1128/IAI.63.7.2706-2713.1995 Kaushik, 2003, Why is trehalose an exceptional protein stabilizer, J Biol Chem, 278, 26458, 10.1074/jbc.M300815200 Kendrick, 1997, Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state, Proc Natl Acad Sci USA, 94, 11917, 10.1073/pnas.94.22.11917 Ohtake, 2011, Trehalose: Current use and future applications, J Pharm Sci, 100, 2020, 10.1002/jps.22458 Wang, 2010, Protein aggregation—Pathways and influencing factors, Int J Pharm, 390, 89, 10.1016/j.ijpharm.2010.02.025 Costantino, 1998, Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone, J Pharm Sci, 87, 1412, 10.1021/js980069t Cleland, 2001, A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody, J Pharm Sci, 90, 310, 10.1002/1520-6017(200103)90:3<310::AID-JPS6>3.0.CO;2-R